

Human FDPS Protein

Cat. No. FDS-HE001



Description

Source	Recombinant Human FDPS Protein is expressed from E.coli with His tag at the N-Terminus. It contains Met1-Lys353.
Accession	NP_001129294.1
Molecular Weight	The protein has a predicted MW of 41.93 kDa same as Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Farnesyl pyrophosphate synthase (FPPS, also known as farnesyl diphosphate synthase (FDPS)) is one of the key enzymes involved in the mevalonate pathway and as such is widely expressed. FPPS modulators, specifically FPPS inhibitors, are useful in treating a number of diseases, including bone-related disorders characterized by excessive bone resorption, for example, osteoporosis, cancer metastasis to bone and infectious diseases caused by certain parasites.


Assay Data

Tris-Bis PAGE



Human FDPS on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human FDPS is greater than 95% as determined by SEC-HPLC.